BIONTECH SE (BNTX): Price and Financial Metrics


BIONTECH SE (BNTX): $238.55

-1.27 (-0.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BNTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

BNTX Stock Summary

  • BNTX's went public 1.47 years ago, making it older than just 1.29% of listed US stocks we're tracking.
  • With a price/sales ratio of 196.3, BioNTech SE has a higher such ratio than 97.53% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, BioNTech SE is reporting a growth rate of 292.66%; that's higher than 94.66% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BioNTech SE are ENTA, MORF, RCUS, NTLA, and MGNX.
  • BNTX's SEC filings can be seen here. And to visit BioNTech SE's official web site, go to www.biontech.de.

BNTX Stock Price Chart Interactive Chart >

Price chart for BNTX

BNTX Price/Volume Stats

Current price $238.55 52-week high $252.78
Prev. close $239.82 52-week low $47.01
Day low $233.61 Volume 1,123,000
Day high $239.78 Avg. volume 2,540,378
50-day MA $179.63 Dividend yield N/A
200-day MA $116.75 Market Cap 57.61B

BIONTECH SE (BNTX) Company Bio


BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders.


BNTX Latest News Stream


Event/Time News Detail
Loading, please wait...

BNTX Latest Social Stream


Loading social stream, please wait...

View Full BNTX Social Stream

Latest BNTX News From Around the Web

Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.

CDC Finds Higher-Than-Expected Heart Inflammation Cases in Young Men Following COVID Vaccine Jabs

In a potentially alarming development, the U.S. Centers for Disease Control and Prevention (CDC) said Thursday that young American men are showing notable increases in heart inflammation conditions after receiving their final coronavirus vaccine shot. Meanwhile, people in that demographic received only 9% of the two-shot regimens of the Moderna (NASDAQ: MRNA) or Pfizer (NYSE: PFE)/BioNTech (NASDAQ: BNTX) vaccines, so the imbalance is clear. Other data show that the median age of vaccinated individuals who developed heart inflammation following their final dose was 24.

Yahoo | June 10, 2021

Moderna, BioNTech Dive On Possible Tie Between Covid Vaccines, Heart Condition

Vaccine stocks toppled Thursday on reports Covid vaccines from Pfizer and Moderna could lead to a heart condition in young recipients.

Yahoo | June 10, 2021

BioNTech SE Stock Earns Membership In 95-Plus Composite Rating Club

The IBD SmartSelect Composite Rating for BioNTech SE Ads rose from 94 to 97 Thursday. The Covid-19 vaccine stock also has 98 Relative Strength Rating. BioNTech SE stock has now climbed above a proper buy zone after breaking out from a 131.10 buy point in a consolidation.

Yahoo | June 10, 2021

Why BioNTech SE Sponsored ADR (BNTX) Might be Well Poised for a Surge

BioNTech SE Sponsored ADR (BNTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Yahoo | June 10, 2021

Moderna’s Covid-19 Vaccine Seeks FDA Authorization for Use in Adolescents

Moderna said it has asked U.S. health regulators to authorize the use of its Covid-19 shot for adolescents ages 12 to 17, potentially lining up a second vaccine option for teens by as soon as July.

Yahoo | June 10, 2021

Read More 'BNTX' Stories Here

BNTX Price Returns

1-mo 23.75%
3-mo 121.13%
6-mo 114.52%
1-year 391.05%
3-year N/A
5-year N/A
YTD 192.63%
2020 140.61%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6683 seconds.